e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

144.28 -0.58 (-0.40%)

Streaming Delayed Price Updated: 10:20 AM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise ↗

February 12, 2024

Shares of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) climbed in early trading on Monday, after several analysts raised their forecasts.

Via Benzinga

Amicus Therapeutics Stock Sees Improved Relative Strength Rating ↗

February 09, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.

Via Investor's Business Daily

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review ↗

February 08, 2024

The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply.

Via Investor's Business Daily

Topics Artificial Intelligence Stocks

Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views ↗

February 08, 2024

Via Benzinga

Earnings Scheduled For February 7, 2024 ↗

February 07, 2024

Companies Reporting Before The Bell • Madison Square Garden (NYSE:MSGE) is expected to report quarterly loss at $0.80 per share on revenue of $301.83 million.

Via Benzinga

Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗

February 07, 2024

Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Earnings Outlook For Neurocrine Biosciences ↗

February 06, 2024

Via Benzinga

NASDAQ:NBIX is not too expensive for the growth it is showing. ↗

February 06, 2024

While growth is established for NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), the stock's valuation remains reasonable.

Via Chartmill

Unveiling 13 Analyst Insights On Neurocrine Biosciences ↗

January 23, 2024

Via Benzinga

NASDAQ:NBIX, a growth stock which is not overvalued. ↗

January 15, 2024

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank.

Via Chartmill

NASDAQ:NBIX, a strong growth stock, setting up for a breakout. ↗

January 12, 2024

Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase.

Via Chartmill

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

Analyst Expectations for Neurocrine Biosciences's Future ↗

December 07, 2023

Via Benzinga

NASDAQ:NBIX: a strong growth stock preparing for the next leg up?. ↗

November 23, 2023

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.

Via Chartmill

VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today ↗

January 02, 2024

VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration.

Via InvestorPlace

Amgen Stock Sees Relative Strength Rating Improve To 74 ↗

December 29, 2023

Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.

Via Investor's Business Daily

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

December 29, 2023

Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.

Via MarketBeat

Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study ↗

December 28, 2023

On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.

Via Investor's Business Daily

Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

December 28, 2023

On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.

Via Investor's Business Daily

Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher ↗

December 26, 2023

On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.

Via Investor's Business Daily

3 Stocks at the Forefront of Medical Innovation ↗

December 25, 2023

Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.

Via InvestorPlace

NASDAQ:NBIX—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗

December 22, 2023

NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), a strong growth stock, setting up for a breakout.

Via Chartmill

Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. ↗

December 22, 2023

While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable.

Via Chartmill

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

December 21, 2023

On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.

Via Investor's Business Daily

The 3 Most Undervalued Biotech Stocks to Buy in December ↗

December 15, 2023

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Via InvestorPlace

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days ↗

December 13, 2023

Cassava Sciences sees its Relative Strength Rating reach the 80-plus level.

Via Investor's Business Daily

Are These Biotechs Ready To Launch? ↗

December 09, 2023

Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...

Via Talk Markets

TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

December 07, 2023

TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.

Via Investor's Business Daily

Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise ↗

December 06, 2023

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX. ↗

December 01, 2023

Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).

Via Chartmill

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy